...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Rotavirus vaccination compliance and completion in a Medicaid infant population
【24h】

Rotavirus vaccination compliance and completion in a Medicaid infant population

机译：轮状病毒疫苗接种的依从性和完成率在Medicaid婴儿人群中

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We examined completion and compliance rates of rotavirus (RV) vaccination according to the recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Food and Drug Administration approved Prescribing Information (PI) for Rotarix (R) (RV1, GlaxoSmithKline Vaccines) and RotaTeq (R) (RV5, Merck and Co.) among infants under one year of age covered by Medicaid programs. Healthcare claims data from state Medicaid programs that constituted the Truven Health MarketScan (R) Multi-State Medicaid Database were retrieved from May 2008-June 2012. Infants were grouped under PI and ACIP cohorts based on the dosing regimens followed. The overall compliance per PI (n = 673,956) and ACIP (n = 695,612) recommendations were 24.5% and 28.2%, respectively; completion rates were 30.3% and 32.6%, respectively. In the PI cohort, infants who received RV1 had significantly higher compliance as compared with infants who received RV5 (65.2% vs. 31.3%; p 0.0001); completion rates among infants receiving RV1 and RV5 were 65.3% and 46.4%, respectively (p 0.0001). In the ACIP cohort, compliance with RV1 was significantly higher than RV5 (68.8% vs. 45.9%; p 0.0001) as was the overall completion rate (73.5% vs. 48.8%; p 0.0001). While compliance is increasing year over year, overall compliance of RV vaccines is suboptimal, with over 40% of eligible infants unvaccinated in both populations. The 2-dose RV vaccine showed better completion rates and higher compliance than the 3-dose RV vaccine in the United States. Public health initiatives focusing on suboptimal compliance and completion rates of RV vaccination in the Medicaid population could improve these metrics, thereby offering protection against RV infection. (C) 2014 The Authors. Published by Elsevier Ltd.
机译：我们根据免疫实践咨询委员会（ACIP）的建议以及美国食品药品管理局批准的Rotarix（R）处方信息（PI）（RV1，葛兰素史克疫苗）和Medicaid计划涵盖的1岁以下婴儿中的RotaTeq（R）（RV5，默克公司）。从2008年5月至2012年6月检索了构成Truven Health MarketScan（R）多州医疗补助数据库的州医疗补助计划的医疗保健数据。根据所遵循的给药方案，将婴儿分为PI和ACIP队列。每个PI（n = 673,956）和ACIP（n = 695,612）建议的总体遵从性分别为24.5％和28.2％;完成率分别为30.3％和32.6％。在PI队列中，接受RV1的婴儿的依从性显着高于接受RV5的婴儿（65.2％比31.3％; p <0.0001）。接受RV1和RV5的婴儿的完成率分别为65.3％和46.4％（p <0.0001）。在ACIP队列中，对RV1的依从性显着高于RV5（68.8％对45.9％; p <0.0001）和整体完成率（73.5％对48.8％; p <0.0001）。尽管依从性逐年提高，但RV疫苗的总体依从性欠佳，两种人群中均超过40％的合格婴儿未接种疫苗。与美国的3剂量RV疫苗相比，2剂量RV疫苗显示出更高的完成率和更高的依从性。重点关注医疗补助人群中非最佳合规性和RV疫苗接种完成率的公共卫生计划可以改善这些指标，从而提供针对RV感染的保护。 （C）2014作者。由Elsevier Ltd.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号